Sanofi names new chief scientific officer amid push to redefine itself

Sanofi named a brand new chief scientific officer this week, a part of a sequence of strikes that the drug firm has argued will set up it as being extra centered on analysis and improvement than prior to now.

In an inner memo obtained by STAT, Sanofi mentioned Monday that it has named Mike Quigley, previously the CEO of startups Dualitas Therapeutics and Therini Bio and senior vp of analysis biology at Gilead, as its chief scientific officer and world head of analysis.

“In his new position, Mike’s mission will likely be to maximise our chance of success by way of optimum collaborations throughout our group and past, bringing greatest in school innovation in addition to creating and sourcing new business main expertise with a dedication to variety,” wrote Houman Ashrafian, the previous enterprise capitalist who’s Sanofi’s head of analysis and improvement. Quigley will report back to Ashrafian and start work on Sept. 30.